GlassScriptPhysician profile
Mark M Archie
NPI 1033553383
$15,617.91
in general payments reported to CMS, 2019-2025
27 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $258 · 2021: $689 · 2022: $1,278 · 2023: $9,702 · 2024: $2,217 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,231 · Food and Beverage: $4,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,231.41 |
| Food and Beverage | $4,859.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,728.94 | 2021-2025 | Endurant Iis, Valiant Captivia, In.Pact Admiral |
| Balt USA, LLC | $1,196.17 | 2024-2025 | Prestige Coil System |
| Silk Road Medical, INC. | $670.09 | 2022-2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Philips North America LLC | $604.84 | 2021-2022 | |
| Shockwave Medical, INC | $597.44 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $501.99 | 2020-2024 | Perclose Prostyle |
| Abiomed | $312.48 | 2024 | Impella |
| Inspiremd LTD | $271.47 | 2025 | Cguard Prime Carotid Stent System |
| Laminate Medical Technologies INC. | $251.00 | 2024-2025 | Vasq External Support, Vasq |
| Medtronic Vascular, INC. | $233.66 | 2019-2020 | |
| Edwards Lifesciences Corporation | $164.20 | 2024 | Sapien 3 Ultra Resilia |
| W. L. Gore & Associates, INC. | $163.55 | 2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control |
| Inari Medical, INC. | $162.42 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bolton Medical INC | $148.34 | 2024-2025 | Treo Abdominal Stent-Graft System, Relay Thoracic Stent-Graft With Plus Delivery System, Gelweave |
| Cordis US Corp. | $132.85 | 2024 | S.M.A.R.T. Control |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $97.68 | 2025 | Rotarexs 6 F X 135 Cm |
| Getinge USA Sales, LLC | $60.67 | 2019 | |
| Cleerly, INC. | $55.97 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Cagent Vascular INC | $52.00 | 2025 | Serrantor |
| Smith+Nephew, INC. | $34.61 | 2022-2023 | Collagenase Santyl |
| Boston Scientific Corporation | $32.29 | 2019 | |
| Covidien LP | $31.57 | 2020 | |
| Janssen Pharmaceuticals, INC | $28.46 | 2024 | Xarelto |
| Acera Surgical, INC. | $27.24 | 2025 | Restrata Wound Matrix |
| Ethicon US, LLC | $25.10 | 2024 | Surgiflo Hemostatic Matrix, Stratafix |
| Cardiovascular Systems INC. | $20.00 | 2019 | |
| Cvrx, INC. | $12.88 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Archie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.